Multicenter screening of diabetic patients for detecting new cases of tuberculosis: An approach to intensify the case detection rate of tuberculosis in developing countries with high prevalence of diabetes by Gadallah, Mohsen et al.
J PREV MED HYG 2019; 60: E343-E348
E343
Introduction. Tuberculosis (TB) is a major public health prob-
lem in most of developing countries. Meanwhile, the prevalence of 
type 2 diabetes mellitus (DM) is also increasing rapidly. 
Objectives. To describe the feasibility of implementing screening 
test for tuberculosis among diabetic patients and identifying fac-
tors associated with high detection rate. 
Methods. Study Design: Multi-center cross-sectional study. This 
study was implemented in the governmental healthcare settings. 
To diagnose TB among diabetics, we used a symptom-based ques-
tionnaire that included the symptoms of suspected TB according 
to the guidelines of National Tuberculosis Program in Egypt. 
Results. Among 4283 adult diabetics, 14 TB cases were diag-
nosed; 9 known TB cases and 5 newly detected cases. The number 
needed to detect one new case of TB was 855. Male diabetics and 
who those suffered from liver disease experienced a significantly 
higher prevalence of TB and a higher detection rate of new active 
cases.
Conclusions. Screening for TB among diabetics in routine gov-
ernmental healthcare services was successfully implemented. 
Screening DM patients in countries with a high prevalence of DM 
will reveal a significant number of active TB cases, which will in 
turn improve the case detection rate of TB. 
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Introduction
Tuberculosis (TB) continues to be the leading killer 
among bacterial diseases worldwide. Globally, in 2017, 
there were an estimated 10.0 million incident cases of 
TB and 1.3 million TB-related deaths [1]. In the same 
year, diabetes mellitus (DM) affected 425 million adults 
and killed 4.0 million people [2]. It is projected that the 
number of people affected by DM will increase to 629 
million by 2045, and approximately 80% of these people 
live in low- and middle-income countries, where TB is 
endemic [2]. The association between DM and TB pre-
sents a major public health problem either in the current 
time or near future especially in low- and middle-income 
countries where TB is endemic disease and the preva-
lence of DM is high and rising. According to a meta-
analysis study, DM patients have a three-fold greater 
risk of contracting TB than do non-diabetics (95% con-
fidence interval [CI]: 2.3-4.3) [3]. Another systematic 
review and meta-analysis done by Al-Rifai et al revealed 
a resilient positive association between DM and TB with 
a substantial variation in the effect size between differ-
ent studies [4]. Other systematic reviews of bidirectional 
screening for TB and DM reported that the prevalence 
of TB among diabetics ranged between 0.38% and 14%, 
with median global value of 4.1% [5, 6]. DM increases 
the risk of developing TB as well as its complications 
e.g. treatment failure, relapse and death rate [7]. Ac-
cordingly, this association has a negative impact on TB 
control program. Screening of high risk group as dia-
betic patients has been part of the Stop TB strategy for 
many years. In 2011, the estimated incidence rate of TB 
in Egypt was 18 per 100,000 populations. In 2017, this 
figure showed improvement, as the estimated incidence 
rate declined to 13 per 100,000 populations [1]. The 
prevalence of DM among those aged 15 to 64 years in-
creased from 15.8% in 2005 to 17.2% in 2011-12 then 
slightly declined to 15.5% in 2017. Accordingly, a large 
proportion of Egyptians will be exposed to the risk of 
DM, and DM patients themselves will be exposed to a 
high risk of acquiring TB. Moreover, patients with both 
TB and DM will be more likely to develop complica-
tions than TB patients without DM [8, 9]. TB screening 
in selected risk groups as persons with DM is considered 
affordable and of low cost and at the same time will im-
prove the low case detection of TB and reduce the delay 
of TB diagnosis [10].
The objectives of this study are to describe the feasibil-
ity of implementing a screening program to screen DM 
patients for TB within the governmental health settings 
affiliated to the Ministry of Health and Population of 
Egypt and identifying factors associated with high de-
tection rate of new TB cases.
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Methods
Study design
This study was a national multicenter cross-sectional 
study. 
Study population and sampling selection
The study population was adult DM patients aged ≥ 18 
years old. All study DM patients were diagnosed by fast-
ing blood sugar (FBS) test (≥ 126 mg/dl) and postpran-
dial blood glucose (PPBG) test (≥ 200 mg/dl). According 
to the last population surveys done in Egypt, the preva-
lence of TB and DM differed in urban and rural areas, 
therefore, in this study a multistage sampling was ap-
plied to represent different geographical areas of Egypt. 
The country was divided geographically into 5 sectors: 
Greater Cairo, the Coastal zone, Upper Egypt, the Suez 
Canal zone, and Lower Egypt. One governorate was se-
lected by a simple random sample from each sector ex-
cept for Lower Egypt due to its high population density; 
in this case, two governorates were selected randomly. 
The selected governorates were Cairo, Alexandria, 
Gharbia, Daqahlia, Ismailia and Suhag. In each selected 
governorate, DM patients who attended outpatient clin-
ics were recruited from all governmental hospitals from 
June 2012 to December 2012. A total of 4283 patients 
were recruited. A simple questionnaire was designed to 
collect data from the DM patients. These data included 
age, gender, residence area (urban/rural), type of treat-
ment of DM, duration of DM (years), history of chronic 
diseases, history of previous TB, details of symptoms of 
suspected TB that used for symptom screening test. 
Diagnosis of TB 
All DM patients were asked about having a history of TB 
i.e. history of previous TB diagnosis (known TB). If the 
answer was yes, then those patients were excluded from 
the screening test but included in the study. If the answer 
was no, then those DM patients were screened first by a 
predesigned questionnaire (screening by symptoms) for 
detecting suspected TB. This symptom screening tool is 
used in Egypt and almost in all developing countries as 
it is cheap and affordable method for detecting suspected 
TB cases especially among high risk groups as diabetic 
patients. According to the Egyptian National TB Pro-
gram, suspected TB was based on having a cough for 
more than 2 weeks, which may be accompanied by other 
respiratory symptoms (e.g., shortness of breath, chest 
pains, and hemoptysis) and/or constitutional symptoms 
(e.g., loss of appetite, weight loss, fever, night sweats, 
and fatigue). DM patients who showed positive symp-
toms suggesting suspected TB were further subjected 
to chest X-ray and sputum analyses (smear and culture) 
for pulmonary TB and histopathology and/or culture for 
extra-pulmonary TB. The validity of this algorithm for 
screening of TB was assessed by World Health Organi-
zation-Guideline Development Group [10] and reported 
the followings: the pooled sensitivity of using symptom 
screening alone was 57% and pooled specificity was 
80%. While using chest radiography these percentages 
increased to 87% for pooled sensitivity and 89% for 
pooled specificity. 
Sample size calculation
Sample size was calculated based on the estimated prev-
alence of TB among DM patients. From reviewing the 
literatures of similar studies in developing countries, the 
prevalence of TB among DM patients was approximate-
ly 2 to 7 times higher than the figure in the population or 
among non-diabetics. In Egypt, the estimated prevalence 
of TB (at the time of the study) among adult population 
was 28 per 100,000 adults. Accordingly, we assumed the 
following assumptions for calculating the sample size of 
the study: An estimated prevalence of 112 per 100,000 
diabetic patients (4 times higher than the figure among 
adult population), 95% confidence level and 0.10% con-
fidence limits. From the above assumptions, a sample 
of 4295 DM patients was required. The sample size was 
calculated using Epi Info version 7. The actual sample 
size in this study with complete records was 4283 DM 
patients.
Ethical approval
The protocol of the study was approved by the Institu-
tional Review Board (IRB) of the faculty of medicine, 
Ain Shams University. All patient data were kept con-
fidential. Informed consent was obtained from each pa-
tient included in the study after having been given a clear 
description of the study objectives. Patients detected by 
the bidirectional screening were referred to specialized 
clinics for further management.
Statistical analysis
All data were analyzed using SPSS version 21. Descrip-
tive analyses with 95% confidence intervals (95% CI) 
were done for all study variables. The only quantitative 
variables in the study were age (years) and duration of 
diabetes (years) and both converted to categorical vari-
ables. Age was classified as two categories (< 50 years 
and ≥ 50 years) while the duration of diabetes was classi-
fied as less than 10 years and ≥ 10 years. The tests of sig-
nificance used for qualitative variables were Chi-square 
test or Fisher’s exact test when appropriate. Binary (sim-
ple and multiple) logistic regression models were used 
for identifying the predictor variables associated with 
the detection of new cases of TB among DM patients 
and to adjust for other confounding variables as age and 
sex. A P value of ≤ 0.05 was considered significant and 
all tests of significance were two tailed.
Results
In this study, 4283 DM patients were recruited from 
different primary healthcare centers (PHCs) and hospi-
tals from the selected study sites. Approximately three-
quarters of the DM patients aged ≥ 50 years, two-thirds 
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were females, 52% were from rural areas, 54.7% had 
DM duration of less than 10 years, approximately half 
of the patients were under insulin therapy, and 4.9% 
also suffered from liver disease. Moreover, three quar-
ters of the diabetic patients included in the study were 
screened at hospitals. Hypertension was reported among 
36.8% of DM patients. In this study, the prevalence of 
known TB was 210.1 per 100,000 population (95% 
CI:110.6-398.6) among DM patients, which was fur-
ther examined by age, sex, residence, screening place 
(PHCs and hospitals), DM treatment type, DM duration 
and chronic disease comorbidities. The results revealed 
that the known prevalence of TB among DM patients 
was higher among those less than 50 years old, males, 
urban residents, those under treatment with oral hypo-
glycemic drugs, those with DM duration of less than 10 
years, and those with liver disease. The prevalence of 
TB was more or less similar among those screened at 
PHC or hospitals (Tab. I). Screening DM patients who 
gave no history of TB (n = 4274) revealed that 261 dia-
betic patients were positive for symptom screening and 
referred for further assessment by chest radiography and 
sputum analyses. The final investigations showed five 
new TB cases, with a detection rate of 117.0 per 100,000 
population (95% CI: 50.0-273.6). This screening de-
tection rate was further analyzed according to patient 
characteristics. A higher screening detection rate of TB 
was reported among males, those aged ≥ 50 years, rural 
residents, those under oral treatment with hypoglycemic 
drugs, those with a DM duration ≥ 10 years, and those 
with liver disease (Tab. II).
The lowest figure of CDR was among female diabetics 
(34.6 per 100,000; 95% CI = 6.1-195.8) while the high-
est value of CDR was reported among diabetic patients 
Tab. I. Prevalence of known TB per 100,000 among DM patients.
Total 
sample
Known 
TB
Prevalence of TB 
(95% CI)
Total 4283 9 210.1 (110.6-398.6)
Age 
< 50
≥ 50
1134
3149
3
6
264.6 (90.0-774.9)
190.5 (87.4-436.7)
Sex
Male
Female
1393
2890
8
1
574.3 (291.3-1129)a
34.6 (6.1–195.7)
Residence
Urban
Rural
2043
2240
6
3
293.7 (134.7-639.3)
133.9 (45.6-393.0)
Screening place
PHC
Hospital
954
3329
2
7
209.6 (60.0-760.0)
210.3 (60.0-430.0)
Treatment
Oral
Insulin
2127
2156
6
3
282.1 (129.4-614.1)
139.1 (47.4-408.9)
Duration of DM
< 10 years
≥ 10 years
2343
1940
7
2
298.8 (144.8-615.4)
103.1 (28.3-375.1)
Chronic disease
None
Liver
Hypertension
Others 
2110
211
1578
384
2
2
3
2
94.8 (26.0–344.9)
947.9 (260.3–3389.0)b
190.1 (64.7–557.4)
520.8 (143.0–1879.0)
a p < 0.001 compared with females
b P = 0.044 compared with none chronic diseases
Tab. II. Screened case detection rate (newly diagnosed) of TB per 100,000 among DM patients with no history of TB.
Total no. screened  
for TB 
A
New cases of TB
B
Screen detection rate 
(95% CI)
A/B * 100,000
Number needed to 
screen
A/B
Total 4274 5 117.0 (50.0-273.6) 855
Age 
< 50
≥ 50
1131
3143
1
4
88.4 (15.6-499.1)
127.3 (49.5-326.8)
1131
786
Sex
Male
Female
1385
2889
4
1
288.8 (112.4-740.2)
34.6 (6.1-195.8)
346
2889
Residence
Urban
Rural
2037
2237
2
3
98.2 (26.9-357.3)
134.1 (45.6-393.5)
1019
746
Screening place
PHC
Hospital
952
3322
0
5
NA
150.5 (60.0-350.0)
NA
664
Treatment
Oral
Insulin
2121
2153
3
2
141.4 (48.1-415.0)
92.9 (25.5-338.1)
707
1077
Duration of DM
< 10 years
≥ 10 years
2336
1938
2
3
85.6 (23.5-311.6)
154.8 (52.7-454.1)
1168
646
Chronic disease
None
Liver
Hypertension
Others
2108
209
1575
382
3
1
1
0
142.3 (48.4-417.6)
478.5 (84.5-2660.0)
63.5 (46.2-1468.0)
NA
703
209
1575
NA
NA = Not Applicable due to zero detected cases
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with liver diseases (478.5 per 100,000).The number 
needed to screen (NNS) to detect one new case of TB 
among diabetics was 855. Furtherly, NNS values were 
calculated according to the patient characteristics. The 
results showed that the lowest value (NNS = 209) was 
found among DM patients with liver disease, followed 
by male patients (NNS = 346). The NNS values ranged 
from 209 to 2889 (Tab. II).
To study factors associated with the total prevalence (di-
agnosed and newly detected cases) of TB among dia-
betics; both bivariate and multivariate logistic regression 
models were applied (Tab. III). The results from the bi-
variate analysis showed that male DM patients and those 
with liver disease had a significantly higher prevalence 
of TB. After adjusting for age and other variables using 
a logistic regression model, both the male gender and the 
presence of liver disease remained as independent risk 
factors, with adjusted odds ratios (AORs) and 95% con-
fidence intervals (CIs) of 12.57 (2.73-57.82) and 6.44 
(1.45-28.72) respectively. 
Discussion
This present study is considered the first national base 
survey in Egypt to study the feasibility of screening the 
comorbidity of TB and DM. Recently, there is growing 
evidence supporting DM as a risk factor for developing 
TB. There are many published reports suggesting the 
mechanisms of developing TB among DM patients, such 
as uncontrolled hyperglycemia, alveolar macrophage 
dysfunction, decrease in monocyte chemotaxis and neu-
trophil count and immune system depression that favors 
infection [11, 12]. However, the mechanism linking DM 
and TB susceptibility requires further study [13]. In this 
study, high prevalence of known TB (previously diag-
nosed elsewhere) among DM patients was found (210.1 
per 100,000), which is 7.5-fold higher than the national 
prevalence of TB (28 per 100,000). Similar to our re-
sults, higher prevalence of TB than national figure was 
reported among diabetic patients in China, Ethiopia, 
India and Mexico [14-18]. Diabetes mellitus is consid-
ered a strong risk factor for developing TB as well as 
worsening the outcome of treatment and increasing the 
mortality rates among comorbid patients (TB with DM). 
Although TB is more associated with other immune 
suppressive diseases as HIV, yet the prevalence of HIV 
in Egypt is very low and the prevalence of diabetes is 
high and with rising prevalence. Therefore, diabetes is 
considered powerful significant risk factor for TB infec-
tion among Egyptian population which in turn adversely 
affects the global TB control [1]. Our results revealed 
that male patients experienced 16.6 fold higher in preva-
lence of TB than females. Also, diabetic patients with 
liver diseases showed higher significant prevalence of 
TB than those without chronic diseases. Other patients’ 
characteristics were insignificantly associated with the 
prevalence of TB such as age, residence, type of treat-
ment and duration of diabetes. Our results were in agree-
ment to the report of Lin et al. [19] in China who re-
ported higher significant increase in the prevalence of 
TB among male diabetics and those with liver cirrhosis 
Tab. III. Factors associated with the total prevalence of TB among DM patients.
Characteristic
Total prevalence of TB (previously diagnosed and newly detected)
Simple logistic regression Multivariate logistic regression
P value
Unadjusted OR
(95% CI)
P value Adjusted OR (95% CI)
Age 
< 50
≥ 50® 0.900 1.11 (0.35-3.55) 0.545 1.63 (0.16-12.90)
Sex
Male
Female® 0.001 12.55(2.80-56.14) 0.001 12.57 (2.73-57.82)
Residence
Urban
Rural® 0.479 1.46 (0.51-5.23) 0.701 0.80 (0.26-2.44)
Screening place
PHC®
Hospital 0.477 1.72 (0.39-7.71) 0.264 2.43 (0.51-11.53)
Treatment
Oral
Insulin® 0.273 1.83 (0.61-5.46) 0.505 1.49 (0.46-4.87)
Duration of DM
< 10 years
≥ 10 years® 0.471 1.49 ( 0.50-4.46) 0.533 1.46 (0.45-4.74)
Chronic illness
None®
Liver 
hypertension
Others 
-
0.005
0.813
0.658
-
6.07 (1.44-25.59) 
1.07 (0.29-3.99)
2.20 (0.43-11.40)
-
0.015
0.529
0.184
-
6.44 (1.45-28.72)
1.55 (0.40-6.01)
3.14 (0.58-16.97)
® Reference group
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in addition to other factors as smoking and subjective 
body loss. Also, Castellanos-Joya et al in Mexico [18] 
reported highly significant increase in the prevalence of 
TB among males and those with history of TB or in con-
tact with TB patients. 
Our screening of DM patients with an unknown history 
of TB detected 5 new cases of TB with a case detection 
rate of 117 per 100,000 population. DM patients face 
frequent infections, which can mainly be attributed to 
hyperglycemia adversely affecting the immune system. 
The highest detection rates of new active cases of TB 
among diabetics were found among those with liver 
diseases (478.5 per 100,000 population, 95% CI = 84.5-
2660.0) and males (288.8 per 100,000 population, 
95%  CI  =112.4-740.2). The NNS of DM patients for 
detecting one new TB patient was 858 with a range be-
tween 209 for those with liver diseases and 2899 for 
female patients. A similar result (NNS = 812) was re-
ported by Prakash et al. in South India [17] while lower 
values were reported as 71 and 490 in Mexico and Gha-
na [18, 21]. The NNS of diabetic patients to find a new 
case of active TB depends mainly on the prevalence of 
TB and DM in the community. Egypt is considered to 
have one of the highest prevalence rates of DM in the 
Middle East; and there is at least 3 million cases with 
DM visiting the healthcare facilities thus, the screening 
of DM patients in Egypt, as well as in similar countries 
with high DM prevalence rates, will yield a significant 
number of new TB cases. When the screened detected 
cases are added to the total number of annual notifiable 
TB cases it will intensify the case detection rate of TB. 
Therefore, screening of DM patients for TB in countries 
with high prevalence of DM and low rate of case detec-
tion is of great importance not only for the proper man-
agement of patients with the double burden of DM and 
TB but also for improving the case detection rate of TB. 
In this study, male diabetics and those with liver disease 
exhibited a significantly higher prevalence of TB and a 
higher detection rate of new active cases. These results 
were confirmed even after adjusting for age and illness 
duration. Most DM patients with liver disease were clas-
sified as such mainly due to hepatitis C virus infection. 
Egypt is considered to have the highest prevalence of 
hepatitis C virus infection  [22]. Therefore, it is of the 
utmost importance when starting to treat DM patients 
with liver disease and TB to closely monitor their liver 
functions, as the first-line drugs for treating TB increase 
the risk of hepatitis (hepatotoxic drugs) and can lead to 
an increase in mortality rate. 
In conclusion, the results of this study showed that 
screening for TB among diabetic patients is feasible and 
could be implemented in a governmental setting. We 
found a high yield of TB among DM patients, and early 
TB detection will improve not only the treatment out-
come of this comorbidity but also the case detection rate 
of TB. Furthermore, the early detection of TB among 
DM patients will reduce the transmission of TB among 
DM patients. The prevalence of TB among diabetics was 
more prominent among males and those with liver dis-
ease. These findings support the advantages of imple-
menting TB screening as a routine investigation during 
the management of diabetes, particularly in developing 
countries with high prevalence of DM and considered 
one of the strategies for addressing TB control and in-
creasing case detection rate.
There are some limitations of this study. The study sam-
ple used for screening diabetic patients for detection of 
TB was restricted only to patients seen in governmental 
hospitals affiliated to the Ministry of Health and Popula-
tion while there are other Universities and private hospi-
tals not included in this study. This is a cross-sectional 
study with the inability to demonstrate a temporal rela-
tionship between exposure and outcome. However, the 
results of this study may throw the light on the potential 
risk factors associated with high detection of new TB 
cases among diabetic patients.
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